Sentences with phrase «treating lung cancer»

My favorite quote: Government - run health care is «akin to treating lung cancer with cough medicine on the advice of Phillip Morris.»

This information will guide our integrated approach to treating lung cancer.

A new drug delivery system for treating lung cancer allow chemotherapeutic drugs to be inhaled, thereby delivering the drug where it is needed while reducing the harmful effects to other organs.

«CRKII most likely regulates the stability of mutated epidermal growth factor receptors and drives cancer growth by promoting signaling, or communication, within cancer cells,» said Julia Petschnigg, lead author on the paper and a postdoctoral fellow at U of T. «We found that a combinatorial chemotherapy that inhibits those mutated receptors and CRKII could be beneficial in treating lung cancer.»

Her experience led her to become a radiation oncologist, and she now works at M.D. Anderson Cancer Center in Houston, Texas, treating lung cancer.

A mechanic doesn't complain about fixing your car because you didn't take care of it, a heart surgeon doesn't complain about your heart attack because you ate too many cheese burgers and a doctor treating lung cancer doesn't complain about all the cigarettes you smoked to get yourself some cancer.

Analysts at the investment bank said the Dow member's sales could boom because of Keytruda, a blockbuster drug used to treat lung cancer.

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

«Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe.»

«Molecule designed to treat lung cancer shows promising results in mice.»

«When we treated lung cancer cells with the antifungal drug, we saw the antiviral protection from IFITM3 pretty much disappear,» explained Christopher Chin, co-first author, also from UMMS.

The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancers.

Results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

The first UK license for CRISPR / Cas9 use in editing genes in human embryos was granted in 2016, xvii and CRISPR - edited cells to treat lung cancer were administered in the world's first human trials for the technique by a Chinese group in late 2016.

Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy treatment.

A study led by Dr. Leena Gandhi suggests immunotherapy should be the new standard of care to treat lung cancer.

A new class of inhibitors offers a novel way to treat lung cancer with minimal toxic side effects on normal cells, according to a laboratory study funded through philanthropic contributions to the Lung Cancer Moon Shot.

Lung Cancer Breakthrough A study published in the September, 1998 issue of Nature Medicine concerned a preliminary trial using gene therapy to treat lung cancer.

Not exact matches

Since then, the companies have been scrambling to rack up indications for the rival drugs, which are both approved for treating melanoma and lung cancer.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Juno also has a few other compounds in early stages of development aimed at treating NHL, pediatric ALL, multiple myeloma, ovarian & breast cancer, AML, lung cancer, and more.

The proportion of patients treated within 62 days of an urgent GP referral for various cancer types is as follows: Lung cancers — 83.3 % treated within 62 days of an urgent GP referral for suspected cancer.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

Gemcitabine is used to treat patients with pancreatic, lung, breast and bladder cancers.

Urbanic said the overall findings of the study suggest that there are some patients with recurrent lung cancers who can be treated with another definitive course of radiation therapy and still have a chance at a cure.

The median age was 66 and the majority of patients (88 percent) were treated for primary lung cancer.

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

The modified toxin could treat asthma, in which lung cells secrete too much mucus, and cancers in which cells overproduce cytokines.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapy.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

It currently is approved to treat certain types of cancers, including melanoma and lung cancer.

The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Both drugs are approved for treating metastatic melanoma, and Opdivo is also approved for squamous lung cancer.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

The FDA has approved several ALK inhibitors for treating non-small cell lung cancer.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

The Americans will treat cancers of the kidney and lung, while the Dutch and the Australians will treat melanoma.

To demonstrate the potential for treating lung disease, the researchers used the nanoparticles to block two genes that have been implicated in lung cancer — VEGF receptor 1 and Dll4, which promote the growth of blood vessels that feed tumors.

For example, the drug crizotinib approved to treat ALK - positive lung cancer, showed a PFS of 10.9 months.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patieLung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patCancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patielung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patcancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

When William Pao was a medical oncology fellow at Memorial Sloan Kettering Cancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy reCancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy recancer (NSCLC) was rote: Every patient received the same chemotherapy regimen.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

Nivolumab is PD - 1 inhibitor, which is used to treat several cancers in their advanced stages, including melanoma, non-small cell lung cancer and kidney cancer.

The drug Gefitinib is used to treat breast, lung, and other cancers by inhibiting epidermal growth factor receptor (EGFR) signaling, but it has only a limited effect on prostate cancer.

Researchers treated ectopic pregnancies — where an embryo implants inside the Fallopian tube — by combining an existing treatment with a lung cancer therapy.